Medical device in-house reveal top challenges for 2021 Counsel at three medical device companies say communication and patent eligibility are some of their biggest hurdles By Rani Mehta March 01 2021
Why companies could flock to the ITC this year Four in-house and private practice lawyers set out why the ITC has become more popular in Q1 of 2021, and why that trend could well continue By Patrick Wingrove February 28 2021
Four ways Amgen v Sanofi will influence in-house strategies Six senior counsel at large pharma companies say the Federal Circuit’s antibody enablement ruling has compelled them to re-think their patenting needs By Patrick Wingrove February 26 2021
MIP Americas Awards 2021: shortlists revealed We have published the Americas shortlists for the 16th annual Managing IP Awards, which will be hosted online this year By Ed Conlon February 24 2021
What black law students want from IP firms Black affinity groups and lunch and learn programming make a big difference to law students when deciding where they want to work By Rani Mehta February 19 2021
In-house reveal how they recover attorney fees in patent cases Counsel from three companies, including Sanofi, delve into when they pursue attorney fees in patent litigation and how private practice lawyers can help By Rani Mehta February 18 2021
Diagnostics firms want American Axle to drive S 101 change In-house patent teams hope SCOTUS will resolve a case from the Federal Circuit and bring much-needed clarity to diagnostic patent eligibility By Charlotte Kilpatrick February 11 2021
FDA approval a ‘real challenge’ for pharma trademarks in 2021 Counsel at four pharma firms, including BMS and Eli Lilly, set out what they need from external partners to get regulatory approval for new drug brands By Patrick Wingrove February 08 2021
Counsel reveal how they pick venue in trade secret cases Lawyers explain how rules of procedure and case histories help them pick between federal and state courts for trade secrets By Rani Mehta February 08 2021
